Hyperuricemia
156
9
16
95
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Published Results
15 trials with published results (10%)
Research Maturity
95 completed trials (61% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
3.8%
6 terminated out of 156 trials
94.1%
+7.5% vs benchmark
18%
28 trials in Phase 3/4
16%
15 of 95 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 95 completed trials
Clinical Trials (156)
Comparison of the Effect of Allopurinol Versus Febuxostat on Serum Uric Acid in Patients With Chronic Kidney Disease Associated With Hyperuricemia
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout
Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout
Mazdutide for Weight Management and Gout in Adults With Obesity
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)
Uric Acid Lowering Trial in Youth Onset T2D
Evaluation of the Effect of Hyperuricemia on Alveolar Bone Loss
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia
Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients
Chronic Kidney Disease and Metabolic Disorders in the Elderly
Prospective Exploratory Study on the Comprehensive Application Effectiveness of Exercise Prescription Decision Support Tools in the Management of Patients With "Four Highs" (Hypertension, Hyperglycemia, Hyperlipidemia, Hyperuricemia)
Treat-to-target by Email During Urate-lowering Therapy in Gout
A Dose Escalation Study of IG3018 in Subjects With Hyperuricemia With or Without Chronic Kidney Disease
A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia
Effectiveness of Digital Health Intervention on Community Health Care in Middle-aged and Older Population in Taiwan
Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients
A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia
Is There a Relationship Between Uric Acid Level and Liver Fibrosis in Obese Patients
Imagery as Biomarker of Gout